The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search feed instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content
| Saunders and Walker

The FDA and drug manufacturer Novartis have issued an alert to healthcare professionals about its drug Myfortic. The drug is used to treat patients with kidney transplants but it has been positively linked to pregnancy loss and congenital malformations. The FDA has stated that Myfortic should not be used in female patients who plan on becoming pregnant due to the increased risk of fetal injury or loss. Accordingly, the FDA has changed Myfortic’s pregnancy category to D which indicates a higher risk of fetal risk.

For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.

Comments are closed.